Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 44Leukemia, Lymphocytic, Chronic, B-Cell 16Myelodysplastic Syndromes 7Leukemia, Biphenotypic, Acute 5Burkitt Lymphoma 5Waldenstrom Macroglobulinemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 3Myeloproliferative Disorders 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hematologic Neoplasms 2Blast Crisis 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, B-Cell 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1Leukemia, Hairy Cell 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 5Cyclophosphamide 5fludarabine 4Biopsy 4Whole-Body Irradiation 3Specimen Handling 3Injections 3Cytarabine 3Busulfan 3venetoclax 2decitabine and cedazuridine drug combination 2Mycophenolic Acid 2CPX-351 2Azacitidine 2thymoglobulin 1quizartinib 1pegylated granulocyte colony-stimulating factor 1peginterferon alfa-2b 1olutasidenib 1canakinumab 1aldesleukin 1X-Rays 1Thiotepa 1Tacrolimus 1Stem Cell Transplantation 1Sirolimus 1Rituximab 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Mass Screening 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Chronic × venetoclax × 30 days × Clear all
NCT03613532 2026-05-20

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
102 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡